Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Britain Courts Anthropic Amid US Defense Department Dispute 
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended June 30, 2017, and provide a general business overview on Wednesday, August 9, 2017, at 4:30 p.m. ET (1:30 p.m. PT).
Conference Call Details
The live conference call on Wednesday, August 9, 2017, at 4:30 p.m. Eastern Time, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765)-507-2588 internationally and using the passcode 61767329. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Mardi Dier, CFO Portola Pharmaceuticals [email protected] Media Contact: Julie Normart Pure Communications [email protected] 415.946.1087
